1. Home
  2. Live Updates
  3. Shannonn westin

Live Breaking News & Updates on Shannonn westin

Stay informed with the latest breaking news from Shannonn westin on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Shannonn westin and stay connected to the pulse of your community

DENALI Study Seeks to Prove Efficacy of Azenosertib in High-Grade Serous Ovarian Cancer

The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.

Texas , United-states , Houston , Shannonn-westin , Department-of-gynecologic-oncology , Womens-health , University-of-texas-md-anderson-cancer-center , Zentalis-pharmaceuticals , Division-of-surgery , Gynecologic-oncology , Reproductive-medicine

Dr Westin on Early Findings With Azenosertib in High-Grade Serous Ovarian Cancer

Shannon N. Westin, MD, MPH, FACOG, discusses the DENALI trial of azenosertib
in patients with high-grade serous ovarian cancer.

Texas , United-states , Shannonn-westin , Division-of-surgery , University-of-texas-md-anderson-cancer-center , Department-of-gynecologic-oncology , Early-drug-development , Ovarian-cancer-moonshot-program , Gynecologic-oncology , Reproductive-medicine , Cancer-center

2023 Yields Several Promising Trial Updates in dMMR/pMMR Endometrial Cancer

Eirwen M. Miller, MD, highlights data that have impacted the treatment armamentarium for patients with endometrial cancer and mismatch repair–deficient or mismatch repair–proficient disease throughout the course of 2023.

Pennsylvania , United-states , Texas , Houston , West-penn , Shannonn-westin , Eirwenm-miller , Christopherb-morse , Allegheny-health-network , University-of-texas-md-anderson-cancer-center , European-society-for-medical-oncology

Oncologists Explore Treatment Options in LGSOC, Look Toward Promising Future

Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development.

Missouri , United-states , Texas , Houston , Washington-university , Orrs , Davidm-omalley , Premalh-thaker , Shannonn-westin , Onclive-news-network , Department-of-obstetrics

Moore Details Ongoing Research Aiming to Fill Unmet Needs in Ovarian Cancer

Kathleen N. Moore, MD, MS, expands on the importance of continuing to investigate PARP inhibitors in ovarian cancer and highlights key updates to have come out of the 2023 ESMO Congress

Oklahoma , United-states , University-of-oklahoma , Houston , Texas , Oklahoma-city , Dana-farber-cancer-institute , Massachusetts , Boston , Joycef-liu , Kathleenn-moore , Floortjej-backes

Maintenance Durvalumab Plus Olaparib Improves PFS in Advanced or Recurrent Endometrial Cancer

The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.



Texas , United-states , Shannonn-westin , P-ann-onc , Astrazeneca , Division-of-surgery , University-of-texas-md-anderson-cancer-center , Department-of-gynecologic-oncology , Gynecologic-oncology , Reproductive-medicine , Cancer-center , Published-october

ESMO: PARP inhibitor plus immunotherapy lowers risk of endometrial cancer progression over chemotherapy alone

ESMO: PARP inhibitor plus immunotherapy lowers risk of endometrial cancer progression over chemotherapy alone
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Texas , United-states , American , America , Shannon-westin , Shannonn-westin , European-society-for-medical-oncology , American-cancer-society , University-of-texas-md-anderson-cancer-center , Astrazeneca , Clinical-oncology , Medical-oncology

Imfinzi and Lynparza Cut Advanced Endometrial Cancer Risk by 45%

Imfinzi and Lynparza Cut Advanced Endometrial Cancer Risk by 45%
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Texas , United-states , Spain , Madrid , America , Shannonn-westin , Lynparza-imfinzi , Susan-galbraith , Astrazeneca , European-society-for-medical-oncology , University-of-texas-md-anderson-cancer-center , Medical-oncology

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

WILMINGTON, Del.--(BUSINESS WIRE)--Oct 21, 2023--

Texas , United-states , Japan , Madrid , Spain , Cambridge , Cambridgeshire , United-kingdom , China , Ottawa , Ontario , Canada

AstraZeneca: IMFINZI (durvalumab) plus LYNPARZA (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

AstraZeneca: IMFINZI (durvalumab) plus LYNPARZA (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Texas , United-states , Japan , Canada , United-kingdom , Ottawa , Ontario , Cambridge , Cambridgeshire , China , Spain , Madrid